FDA declines to grant accelerated approval for Eli Lilly's experimental Alzheimer's treatment

The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer's drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker.

from CNN.com - RSS Channel https://ift.tt/fLy5o9z